Biomerica Inc
NASDAQ:BMRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sugal and Damani Share Brokers Ltd
BSE:511654
|
IN |
|
Oversea-Chinese Banking Corporation Ltd
OTC:OVCHY
|
SG |
|
B
|
Better Plant Sciences Inc
OTC:VEGGD
|
CA |
|
Societe LDC SA
LSE:0RJ6
|
FR |
Biomerica Inc
Net Issuance of Common Stock
Biomerica Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomerica Inc
NASDAQ:BMRA
|
Net Issuance of Common Stock
$1.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
40%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Issuance of Common Stock
$282m
|
CAGR 3-Years
24%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
12%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Issuance of Common Stock
-$719.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-5%
|
|
|
Stryker Corp
NYSE:SYK
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Issuance of Common Stock
-$497m
|
CAGR 3-Years
36%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Issuance of Common Stock
-$1.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biomerica Inc
Glance View
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 49 full-time employees. The firm develops, patents, manufactures and markets diagnostic and therapeutic products for the early detection and monitoring of chronic diseases and other medical conditions. The firm's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the of specific bacteria, hormones, antibodies, antigens, or other substances, in a patient body, stools, or blood, saliva or nasal fluid. The firm is engaged in research and development of disruptive, patented diagnostic guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases.
See Also
What is Biomerica Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
1.5m
USD
Based on the financial report for Feb 28, 2026, Biomerica Inc's Net Issuance of Common Stock amounts to 1.5m USD.
What is Biomerica Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
40%
Over the last year, the Net Issuance of Common Stock growth was -31%. The average annual Net Issuance of Common Stock growth rates for Biomerica Inc have been -12% over the past three years , -33% over the past five years , and 40% over the past ten years .
